Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
In what circumstance, if any, would you consider PARP inhibition in metastatic BRCA wild type TNBC who has exhausted all other treatment options?
Does LOH or VUS play a role in your decision?
Related Questions
What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
Is Tucatinib as cardiotoxic as other anti HER2 agents?
What is your preferred first line therapy for metastatic HR+ inflammatory breast cancer?
When should paclitaxel (or other chemo) be discontinued in de novo metastatic triple negative breast cancer with high PDL1 in favor of continuing pembrolizumab alone with good treatment response?
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
Do you switch therapy to sacituzumab in a patient with metastatic HR+ HER2- breast cancer who has stable systemic disease but new <1cm brain metastasis?
Is there a role of adding hormonal therapy to fam-trastuzumab deruxtecan in patients with metastatic ER/PR+ HER2 low breast cancer after progressing on aromatase inhibitor and CDK4/6i?
In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?